Literature DB >> 29091534

American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.

.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29091534     DOI： 10.1200/JOP.2017.027359

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  7 in total

Review 1.  Impact of Pharmacy Benefit Managers on Oncology Practices and Patients.

Authors:  Trevor J Royce; Caroline Schenkel; Kelsey Kirkwood; Laura Levit; Kathryn Levit; Sheetal Kircher
Journal:  JCO Oncol Pract       Date:  2020-04-20

2.  Impact of Cost Conversation on Decision-Making Outcomes.

Authors:  Nataly R Espinoza Suarez; Christina M LaVecchia; Karen M Fischer; Celia C Kamath; Juan P Brito
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-06-12

3.  The Cancer Financial Experience (CAFÉ) study: randomized controlled trial of a financial navigation intervention to address cancer-related financial hardship.

Authors:  Nora B Henrikson; Melissa L Anderson; John Dickerson; John J Ewing; Robin Garcia; Erin Keast; Deborah A King; Cara Lewis; Blake Locher; Carmit McMullen; Consuelo M Norris; Amanda F Petrik; Arvind Ramaprasan; Jennifer S Rivelli; Jennifer L Schneider; Lisa Shulman; Leah Tuzzio; Matthew P Banegas
Journal:  Trials       Date:  2022-05-13       Impact factor: 2.728

4.  The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?

Authors:  Whitney N Goldsberry; Sarah S Summerlin; Allison Guyton; Brittani Caddell; Warner K Huh; Kenneth H Kim; Margaret I Liang
Journal:  Gynecol Oncol       Date:  2021-01-04       Impact factor: 5.482

5.  Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.

Authors:  Margaret I Liang; Ling Chen; Dawn L Hershman; Grace C Hillyer; Warner K Huh; Allison Guyton; Jason D Wright
Journal:  Gynecol Oncol       Date:  2020-12-27       Impact factor: 5.482

6.  The insurability of innovative pharmaceutical cancer technologies.

Authors:  Shuli Brammli Greenberg; Einat Dotan; Rachel Arazi
Journal:  Isr J Health Policy Res       Date:  2020-12-21

7.  Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.

Authors:  Hong Zhu; Jingmin Zhu; Yingyu Zhou; Linghan Shan; Cui Li; Yu Cui; Zheng Kang; Mingli Jiao; Huan Liu; Lijun Gao; Qunhong Wu; Yanhua Hao
Journal:  Front Public Health       Date:  2022-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.